Group 1 - The core viewpoint is that the Hong Kong innovative drug sector is experiencing significant growth, driven by supportive government policies and increased participation in international events like the JPMorgan Healthcare Conference [1][2] - The National Index for Hong Kong Innovative Drugs has seen a strong increase of 5.21% as of April 10, 2025, with notable gains in constituent stocks such as WuXi AppTec (up 14.19%) and Kelun-Biotech (up 12.95%) [1] - The Hong Kong Innovative Drug ETF (159567) has also performed well, rising 8.00% recently and showing a cumulative increase of 14.88% over the past three months, ranking in the top third among comparable funds [1] Group 2 - The 43rd JPMorgan Healthcare Conference in San Francisco highlighted the active participation of Chinese innovative drug companies, indicating a promising outlook for the industry with expected project collaborations and pipeline advancements in 2025 [2] - The Hong Kong Innovative Drug ETF closely tracks the National Index for Hong Kong Innovative Drugs, allowing for T+0 trading and reflecting the operational characteristics of listed companies in the innovative drug sector [2] Group 3 - As of April 9, 2025, the Hong Kong Innovative Drug ETF has seen an average daily trading volume of 827 million yuan over the past week, with a total net inflow of 426 million yuan in the last eight days [3] - The ETF's net asset value has increased by 26.67% over the past year, ranking it in the top 8.52% among 2710 index equity funds [3] - The current price-to-earnings ratio (PE-TTM) of the index tracked by the ETF is 24.3, indicating a valuation that is lower than 98.9% of the time over the past year, suggesting it is at a historical low [3]
涨幅8%！对等关税或有谈判转机，港股创新药ETF（159567）今日强势反弹，T+0交易市场交投活跃，实时成交额超2.17亿元
Mei Ri Jing Ji Xin Wen·2025-04-10 02:04